Zydus Cadila

New Delhi: ZyCoV-D, which was cleared by the DCGI in August last year, has started supplying the first batch of the vaccine to the Union government, said the company. "We have started the supply of the three-dose ZyCoV-D to the…

Bhubaneswar: While Zycov-D, India’s first COVID-19 vaccine for those above 12, was approved by Drug Controller General, Director of Medical Education & Training (DMET) Dr CBK Mohanty said that the process to vaccinate above 12-year-old…

Bengaluru: India's drug regulator approved Zydus Cadila's three-dose COVID-19 DNA vaccine for emergency use in adults and children aged 12 years and above, bringing in the sixth vaccine authorised for use in the country. The company said…

New Delhi: Zydus Cadila has received approval for Emergency Use Authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D today, the world’s first and India’s indigenously developed DNA based vaccine for COVID-19 to…

New Delhi: Zydus Cadila today announced that the company has applied for Emergency Use Authorization (EUA) to the office of Drug Controller General of India (DCGI) for ZyCoV-D. An approval for Zydus' vaccine, ZyCoV-D, would make it the…

New Delhi: The National Technical Advisory Group on Immunisation (NTAGI) chairman Dr NK Arora on Sunday said that the Covid-19 vaccine developed for children above the age of 12 years by pharmaceutical company Zydus Cadila will be available…

New Delhi: Zydus Cadila, which is developing DNA vaccines, has concluded its clinical trial for children between the age group of 12 to 18 years and the shots will be available soon, informed the Central government to Supreme Court. "It…

New Delhi: India's Zydus Cadila has sought DCGI (Drugs Controller General of India) nod to undertake clinical trials of its antibody cocktail that can neutralise Covid infection. ZRC-3308 is a cocktail of 2 anti-SARS-CoV-2 monoclonal…

New Delhi: Zydus Cadila on Monday announced that it has sought national drugs controller’s approval for use of its viral hepatitis drug. It has announced that its Phase III clinical trials with Pegylated Interferon Alpha 2b, PegiHepTM…